Efficacy of a Combination of Flumazenil and Gabapentin in the Treatment of Alcohol Dependence: Relationship to Alcohol Withdrawal Symptoms
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Improved treatment of alcohol dependence is a high priority, including defining subtypes that might respond differently. We evaluated a medication combination of intravenous flumazenil (FMZ) and oral gabapentin (GBP) in alcoholics who did and did not exhibit pretreatment alcohol withdrawal (AW) symptoms. Sixty alcohol-dependent individuals (44 with low AW and 16 with high AW) were randomized to receive FMZ (2 mg of incremental bolus for 20 minutes for 2 consecutive days) and GBP (up to 1200 mg nightly for 39 days) or their inactive placebos. Alcohol withdrawal was measured for the first 2 days, and drinking, sleep parameters, and adverse events were monitored during weekly evaluations, along with behavioral counseling sessions. Percent days abstinent (PDA) during treatment and time to first heavy drinking (TFHD) day were primary outcome variables. There was an interaction between the pretreatment AW status and the medication group on PDA (P = 0.0006) and TFHD (P = 0.06). Those in the high AW group had more PDA and more TFHD if treated with active medications, whereas those in the low AW group had more PDA and more TFHD if treated with placebo. This interaction remained for those totally abstinent (P = 0.03) and was confirmed by percent carbohydrate-deficient transferrin values. In addition, the pattern of response remained up to 8 weeks after treatment. In addition, in those with high AW, greater improvement in AW symptoms was observed in the active medication group compared with the placebo group. These results suggest a differential response to FMZ/GBP treatment, depending on pretreatment AW status that should be taken into account during future treatment trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 1×
“Subjects completed the following assessments before randomization: the timeline follow-back interview for daily drinking,(34) the Alcohol Dependence Scale (ADS),(35) the ObsessiveCompulsive Drinking Scale (OCDS),(36) the Profile of Mood States,(37) the Epworth Sleepiness Scale,(38) the Pittsburg Sleep Quality Index,39…”
MethodGABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid
Smith, S. S., Gong, Q. H., Hsu, F.-C., Markowitz, R. S., ffrench-Mullen, J. M. H., & Li, X. (1998) · Nature · doi:10.1038/31948 · Cited by 564
Furieri, F. A., & Nakamura-Palacios, E. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1108 · Cited by 144 · cited 1×
“In addition, in a 4-week randomized controlled clinical trial of 60 alcohol-dependent men, it was reported that gabapentin (300 mg twice daily) was more efficacious than placebo in reducing drinking and craving and was well tolerated.(31) Of interest in this study were participants who were very heavy drinkers (mean o…”
BackgroundSB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats
Knapp, D. J., Overstreet, D. H., Moy, S. S., & Breese, G. R. (2004) · Alcohol · doi:10.1016/j.alcohol.2003.08.007 · Cited by 130
Cellular and behavioral interactions of gabapentin with alcohol dependence
Roberto, M., Gilpin, N. W., O'Dell, L. E., Cruz, M. T., Morse, A. C., Siggins, G. R., & Koob, G. F. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-08.2008 · Cited by 126
Cited by
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 592
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Anton, R. F., Latham, P., Voronin, K., Book, S., Hoffman, M., Prisciandaro, J., & Bristol, E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0249 · Cited by 186
Self-citationNovel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“While these findings may be related to potential pharmacokinetic issues relating to the specific formulation of extended-release gabapentin used in the trial, it is also possible that gabapentin may simply be more effective in patients with more clinically relevant and severe symptoms of alcohol withdrawal [130, 134].”
BackgroundResultAssessment and treatment of insomnia in adult patients with alcohol use disorders
Brower, K. J. (2015) · Alcohol · doi:10.1016/j.alcohol.2014.12.003 · Cited by 134
Metadata
- Authors
- Anton, R. F., Myrick, H., Baros, A. M., Latham, P. K., Randall, P. K., Wright, T. M., Stewart, S. H., Waid, R., & Malcolm, R.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2009-08
- Volume
- 29
- Issue
- 4
- Pages
- 334-342
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2050505630
- Cited by
- 75
- References
- 6
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of a Combination of Flumazenil and Gabapentin in the Treatment of Alcohol Dependence: Relationship to Alcohol Withdrawal Symptoms. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181aba6a4
- The paper
- Anton, R. F., Myrick, H., Baros, A. M., Latham, P. K., Randall, P. K., Wright, T. M., Stewart, S. H., Waid, R., & Malcolm, R. (2009). Efficacy of a Combination of Flumazenil and Gabapentin in the Treatment of Alcohol Dependence: Relationship to Alcohol Withdrawal Symptoms. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181aba6a4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.